BPC-157 for Wound Healing: What the Long-Term Follow-Up Data Actually Show

What Is BPC-157 and Why Is It Used Off-Label?

BPC-157 stands for Body Protection Compound-157. It is a synthetic 15-amino-acid peptide derived from a partial sequence of a human gastric protein first isolated in the 1990s. Researchers at the University of Zagreb, led by Predrag Sikiric, identified it as a fragment of BPC (body protection compound) found naturally in gastric juice, and published early regenerative findings beginning in 1993.

The peptide has no FDA-approved indication. Every clinical application you will read about online, including wound healing, tendon repair, gut restoration, and joint recovery, is off-label. In the United States, BPC-157 is not an approved drug, and the FDA has specifically flagged compounded BPC-157 as a substance of concern regarding compounding pharmacy use.

That context matters before anything else.

How the Peptide Is Thought to Work

BPC-157 appears to act on several overlapping repair pathways. Rodent studies suggest it upregulates nitric oxide (NO) production, stimulates growth hormone receptor expression in tendon fibroblasts, and promotes angiogenesis through vascular endothelial growth factor (VEGF)-dependent and VEGF-independent routes, as described in a 2018 review in the Journal of Physiology and Pharmacology.

It also modulates the dopaminergic and serotonergic systems. That matters for women specifically, because serotonin turnover changes across the menstrual cycle and during perimenopause, though no study has examined whether cycle phase alters BPC-157 pharmacokinetics or pharmacodynamics.

Routes of Administration Studied

Animal protocols have used subcutaneous injection, intramuscular injection, intraperitoneal injection, and oral gavage. Bioavailability data in humans simply do not exist in the published literature. Oral stability of peptides is generally poor due to proteolytic degradation in the gut, though some preclinical work suggests BPC-157 may be unusually stable in gastric acid compared with other peptides, per Sikiric et al., 2016.

What Long-Term Follow-Up Studies Actually Exist

This is the core question, and the honest answer is: the long-term data are thin, entirely preclinical, and were not designed with women's physiology in mind.

Rodent Long-Term Wound Healing Studies

The most cited long-term wound healing work comes from Sikiric's group at Zagreb. A series of rat studies examined full-thickness skin wounds, colon anastomoses, and esophageal lesions over periods ranging from 7 days to 12 weeks. A 2019 paper in Frontiers in Pharmacology summarized findings showing that BPC-157-treated animals had superior wound closure rates at days 7, 14, and 28 compared with saline controls, with histology at 12 weeks showing more organized collagen deposition and fewer adhesions.

A key number from that work: wound-closure area at day 14 was approximately 85-90% in BPC-157 groups versus 60-70% in controls, though effect sizes varied by wound model. Statistical significance was reported at p < 0.05 across most endpoints.

At 12 weeks, the treated groups also showed lower rates of fibrotic scar formation in gut anastomosis models, which is a relevant endpoint because excessive fibrosis underlies post-surgical adhesion formation, a condition that disproportionately affects women who have had abdominal gynecologic procedures.

Tendon and Musculoskeletal Long-Term Data

A frequently cited tendon study by Brcic et al. Followed Achilles tendon transection repair in rats for up to 6 months. Published in the Journal of Orthopaedic Research in 2009, it found that BPC-157-treated tendons showed better biomechanical properties (load to failure, stiffness) at 4 and 6 months compared with controls. The 6-month data are among the longest published follow-up periods for this compound in any model.

Critically, both male and female rats were not segregated in most of these studies. Sex was not reported as a variable. This is a systematic gap.

What "Long-Term" Means in This Literature

In BPC-157 research, "long-term" means weeks to a few months in rodents. No study has followed animals beyond 6 months. No human follow-up study exists at all. When a wellness provider tells you there is "long-term evidence" for BPC-157 in wound healing, that claim rests entirely on rodent data with follow-up of up to 6 months, zero human controlled trials, and a literature dominated by a single research group.

That is not a dismissal of the science. It is an accurate statement of where the evidence stands in early 2025.

Sex-Specific Physiology: What Changes for Women

Most peptide research, including the BPC-157 literature, has been conducted in male rodents or in mixed-sex groups without sex-stratified analysis. Here is a framework for thinking about how female biology may intersect with BPC-157's proposed mechanisms, organized by life stage.

Reproductive Years (Ages 18 to ~45)

Estrogen is a potent modulator of wound healing. It accelerates re-epithelialization, reduces inflammatory cytokine production, and increases collagen synthesis. A landmark paper by Ashcroft et al. In Nature Medicine (1997) demonstrated that estrogen deficiency impairs wound healing significantly in aged rodents and postmenopausal women, and topical estrogen reversed that impairment.

If BPC-157 acts partly through collagen organization and angiogenesis, as the animal data suggest, it is biologically plausible that its effects would differ between a 28-year-old woman in the follicular phase and a postmenopausal woman with low estrogen. No study has tested this. Women in reproductive years also have cyclically fluctuating progesterone, which has immunosuppressive effects in the luteal phase that could alter wound inflammatory dynamics. This interaction with BPC-157 is completely unstudied.

Women with PCOS are particularly relevant here. PCOS is associated with impaired wound healing due to hyperinsulinemia, chronic low-grade inflammation, and androgen excess. BPC-157's proposed anti-inflammatory and angiogenic effects could theoretically be relevant to this population, but no PCOS-specific data exist.

Perimenopause (Roughly Ages 45 to 55)

Estrogen levels fluctuate widely during the menopausal transition. Skin collagen content declines by approximately 30% in the first five years after menopause, and wound healing slows measurably. Perimenopausal women undergoing gynecologic surgery, or managing post-procedural wounds, represent a group where enhanced tissue repair would be clinically meaningful.

BPC-157 has not been studied in estrogen-deficient states. Whether its collagen-promoting effects are estrogen-dependent, additive to estrogen, or independent is unknown.

Postmenopause

The collagen deficit and vascular changes of the postmenopausal state create a biological context where any pro-regenerative agent might theoretically offer benefit, but also where systemic effects on vascular tone, a proposed BPC-157 action, could carry different risk profiles than in younger women.

Postmenopausal women are also more likely to be managing multiple medications (antihypertensives, statins, bisphosphonates), and BPC-157's drug interaction profile in humans is entirely undocumented.

Pregnancy and Lactation Safety

BPC-157 should not be used during pregnancy or while breastfeeding. This is not a precautionary hedge. It reflects a complete absence of human safety data and the biological reality that any bioactive peptide with growth-promoting and vascular effects carries theoretical risks during fetal development and in a nursing infant.

Pregnancy

No animal teratogenicity studies have been published using standard developmental toxicology protocols. No human pregnancy exposure data exist. BPC-157 promotes angiogenesis and modulates growth factor signaling, pathways that are tightly regulated during placental development and organogenesis. The FDA has not assigned a pregnancy category because BPC-157 is not an approved drug, but by analogy to other vasoactive growth-promoting peptides, the precautionary principle clearly applies.

If you are pregnant or trying to conceive, do not use BPC-157.

Lactation

No data exist on BPC-157 transfer into human breast milk. Peptides of this size (molecular weight approximately 1,419 Da) may or may not transfer into milk in biologically significant amounts, depending on their oral bioavailability and transport properties. The theoretical risk to a nursing infant cannot be quantified. Avoidance during breastfeeding is the appropriate recommendation.

Contraception

Women of reproductive age who choose to use BPC-157 (understanding the off-label and unproven nature of its use) should use reliable contraception. If you are using hormonal contraception, note that no interaction data between BPC-157 and any hormonal contraceptive exist. There is no known mechanism for interference, but that is an absence of evidence, not evidence of absence.

Who This May Be Right For and Who Should Avoid It

This is genuinely difficult to frame, because without human trial data, no clinician can say with confidence that BPC-157 is appropriate for any specific patient. What can be said is this.

Potentially Interested Women (With Strong Caveats)

Women who may be considering BPC-157 for wound healing support include those managing slow-healing post-surgical wounds after gynecologic procedures (laparoscopy, myomectomy, cesarean), those with PCOS-related skin or soft tissue healing concerns, and athletes with tendon or muscle injuries who have not responded to standard care. All of these groups deserve honest counseling: the data supporting BPC-157 in any of these scenarios come exclusively from rodent models, and the 2021 narrative review by Gwyer et al. In Drug Design, Development and Therapy explicitly notes that human evidence remains absent.

Women Who Should Not Use BPC-157

Anyone who is pregnant, breastfeeding, or actively trying to conceive should not use this compound. Women with a personal or family history of hormone-sensitive tumors should also avoid it, given that BPC-157 promotes angiogenesis and growth factor signaling, neither of which has been studied in oncologic contexts in women. Women taking immunosuppressants after organ transplant, or those with complex medication regimens, should not add an unstudied peptide without specialist guidance.

Women with endometriosis are a particular concern. Endometriotic lesions are angiogenesis-dependent, and VEGF plays a central role in endometriosis progression. A compound that promotes angiogenesis could theoretically worsen endometriosis. No study has examined this. The risk is theoretical but not dismissible.

The Evidence Gap: Women Were Missing From This Research

The BPC-157 literature is a case study in how preclinical research fails women. Of the major long-term wound healing studies published between 1993 and 2024, nearly all used male Sprague-Dawley or Wistar rats, or mixed-sex groups without reporting sex as a biological variable. The 2019 Frontiers in Pharmacology review does not stratify any outcome by sex. The Brcic 2009 tendon study does not report the sex distribution of animals used.

This matters because sex differences in wound healing are well-documented. A 2020 meta-analysis in Biology of Sex Differences found that female rodents heal faster than male rodents in standard wound models, driven primarily by estrogen-mediated differences in macrophage polarization and keratinocyte migration. If female rodents heal faster at baseline, the effect size of BPC-157 may be meaningfully different in females compared with the male-dominant preclinical results reported.

As a result, extrapolating the existing BPC-157 wound healing data to women requires acknowledging that you are relying on male-default biology. This is a significant limitation that wellness providers rarely mention.

What Current Guidelines Say

No major guideline body has issued guidance on BPC-157 for wound healing. The ACOG has no position statement. The American College of Clinical Wound Care has not endorsed it. The Menopause Society has no recommendation. The World Health Organization does not include BPC-157 in its essential medicines list or any wound care framework.

Standard of care for wound healing in women includes moist wound dressings, appropriate debridement, infection control, nutritional optimization (particularly protein and zinc), and management of underlying conditions such as diabetes, PCOS-related insulin resistance, and hormonal deficiencies. In postmenopausal women with systemic estrogen deficiency, addressing estrogen status through evidence-based hormone therapy is supported by ACOG Practice Bulletin data and has a direct physiologic rationale for tissue repair that BPC-157 currently cannot match in terms of evidence strength.

Regulatory and Sourcing Concerns

BPC-157 is sold in the United States primarily through compounding pharmacies and research chemical suppliers. In 2022 and 2023, the FDA updated its list of bulk drug substances to flag BPC-157 as a substance that has not been found suitable for compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. This means compounding pharmacies operating legally cannot include BPC-157 in compounded preparations for human use in a straightforward regulatory pathway.

Purity, sterility, and accurate dosing in products labeled as BPC-157 are not guaranteed. Third-party testing of peptide research chemicals has found significant variation in peptide content and contamination with bacterial endotoxins. For a woman considering subcutaneous injection of a compounded or research-grade peptide, sterility failures carry real infection risk, including abscess formation and systemic sepsis.

If you are interested in exploring BPC-157 with a provider, ask specifically how any product has been tested, where it is sourced, and what the provider's plan is if you experience an adverse reaction. Any provider who cannot answer those questions clearly is not practicing appropriate prescribing.

Practical Takeaways if You Are Considering BPC-157

The decision to use an off-label, unapproved compound sits entirely with you and a clinician who knows your full medical history. These are the questions worth asking before you proceed.

First, is there a standard-of-care intervention you have not yet tried? Post-surgical wound healing, tendon injuries, and gut healing all have evidence-based treatment protocols. BPC-157 should not be a first-line choice.

Second, what is your hormonal status? A perimenopausal woman managing a slow-healing surgical wound may benefit more from addressing estrogen deficiency, based on published evidence in the British Journal of Dermatology, than from an unstudied peptide.

Third, are you in any of the categories for whom BPC-157 is clearly inappropriate? Pregnancy, active breastfeeding, endometriosis, or history of hormone-sensitive cancer are clear reasons to avoid this compound.

Fourth, if you proceed, insist on pharmaceutical-grade compounded product with a certificate of analysis confirming peptide identity, purity above 98%, and endotoxin testing. Do not use research-chemical-grade BPC-157 intended for lab use.

The maximum duration of any follow-up in the published literature is 6 months in rodents, per Brcic et al., 2009. There is simply no basis for claiming knowledge of what BPC-157 does in humans over 1 year, 2 years, or longer. Any provider or website making long-term safety or efficacy claims about this compound in women is stating something the published evidence does not support.